Registration is open for the 2024 ASRM Scientific Congress & Expo

Close Close Icon

Evaluation and treatment of recurrent pregnancy loss: a committee opinion (2012)

Clinically recognized pregnancy loss is common, occurring in approximately 15–25% of pregnancies. The majority of sporadic losses before 10 weeks’ gestation result from random numeric chromosome errors, specifically, trisomy, monosomy, and polyploidy (1). In contrast, recurrent pregnancy loss (RPL) is a distinct disorder defined by two ormore failed clinical pregnancies (2). It is estimated that fewer than 5%ofwomenwill experience two consecutive miscarriages, and only 1% experience three or more (3).


The challenge for clinicians is to differentiate sporadic miscarriage from RPL. Self-reported losses by patients may not be accurate. In one study, only 71% of self-reported clinical pregnancy losses could be verified in hospital records (4). For the purposes of determining whether evaluation for RPL is appropriate, pregnancy is defined as a clinical pregnancy documented by ultrasonography or histopathological examination. Ideally, a threshold of three or more losses should be used for epidemiological studies while clinical evaluation may proceed following two first-trimester pregnancy losses.


Studies that focus on RPL have examined factors related to genetics, age, antiphospholipid syndrome, uterine anomalies, thrombophilias, hormonal or metabolic disorders, infection, autoimmunity, sperm quality, and lifestyle issues (Table 1). Several recommendations have been published (5, 6) regarding the evaluation and management of RPL. These publications do not support definitive conclusions about the causes of RPL because most studies of pregnancy loss have focused on sporadic miscarriage and not RPL. A putative diagnosis will be made and treated in approximately 50% of patients with RPL (7, 8). The following overview acknowledges that our understanding of this field is in flux.

Cytogenetic Abnormalities in Pregnancy Loss

Virtually every published set of recommendations and reviews on this topic agrees that genetic causes should be evaluated and appropriate treatments considered (4–6, 9). Unfortunately, clinical genetic testing remains rudimentary and rarely includes molecular studies which show promise in helping to elucidate mechanisms for RPL. There is a very high frequency of sporadic karyotypic abnormalities in products of conception while the incidence of karyotypic abnormalities in the parents is low.

Of the examined products of conception, approximately 60% of early pregnancy losses are associated with sporadic chromosomal anomalies, primarily trisomies that are, in part, age related (1, 10, 11). In those losses with a normal karyotype, gross morphological abnormalities in the fetus diagnosed by transcervical embryoscopy have been described in 18% of patients (12). The risk of sporadic miscarriage between 6 and 12 weeks of gestation in women less than 35 years of age is 9% to 12% (13, 14). The risk increases in women over 35 years of age due to the markedly increased incidence of trisomic pregnancies (10). In women older than 40 years of age, the sporadic miscarriage rate approaches 50% (1, 14, 15) (Fig. 1). The risk of aneuploidy at each age is lower in women with RPL than in those who undergo sporadic miscarriages (11).

Table 1. Suspected causes of recurrent pregnancy loss.

ause Contribution to RPL (%) Recommended screening Supportive scientific evidence Controversial scientific evidence Not recommended
Cytogenetic 2–5 Balanced reciprocal
aPL syndrome 8–42 (mean, 15) Lupus anticoagulant,
anticardiolipin IgG
or IgM antibody,
anti-β2-glycoprotein I
IgG and IgM antibodies,
aPL testing for other
phospholipids and β2
glycoprotein I
IgG or IgM anti-annexin A5,
anti-factor XII, antiprothrombin,
IgA aPLs
ANA, antithyroid antibodies
Anatomic 1.8–37.6 (mean, 12.6) Hysterosalpingography
Congenital uterine
Uterine fibroids, polyps Cervical incompetence
Hormonal or metabolic  

Hemoglobin A1c

Uncontrolled diabetes
or thyroid disease, prolactin
Polycystic ovary syndrome and
insulin resistance, luteal
phase progesterone
Infectious   None   Bacterial vaginosis, endocervical
Male factors   None   Abnormal sperm DNA  
Psychological   None   Psychological effects on uterine
Alloimmune   None   Mucosal CD16 NK cells,
embryotoxic factor, cytokine
profiles, blocking antibodies,
HLA typing, anti-paternal
leukocyte antibodies,
circulating CD16 NK cells
Circulating CD16 NK cells
Environnmental, occupational,
or personal habits
  History     Not related to recurrent
pregnancy loss
Note: ANA = antinuclear antibodies; aPL = antiphospholipid

Figure 1

In the evaluation of RPL, parents should undergo peripheral karyotyping in order to detect any balanced structural chromosomal abnormalities. Balanced reciprocal translocations and Robertsonian translocations (6) are observed in about 2%–5% of couples with recurrent miscarriage.

Genetic counseling is important when a structural genetic factor is identified. The likelihood of a subsequent healthy live birth depends on the chromosome(s) involved and the type of rearrangement. When one of the partners has a structural genetic abnormality, preimplantation genetic testing (PGT), amniocentesis, or chorionic villus sampling are options to detect the genetic abnormality in the offspring. Treatment options include preimplantation genetic diagnosis (PGD) for specific translocations, with transfer of unaffected embryos, or the use of donor gametes. While data are limited comparing in vitro fertilization (IVF)/PGD versus medical management (defined as natural conception and observation) for couples with RPL carrying a structural genetic abnormality, two systematic reviews have summarized the success rates from the literature (16, 17). In these reviews, live birth rates were estimated to be between 31%–35% per cycle for IVF/PGD and cumulative live birth rates were 55%–74% for natural conception/medical management. Therefore, there are insufficient data demonstrating that IVF/PGD improves live birth rate in couples with RPL and a structural genetic abnormality. Based on limited cytogenetic data, 36%–39% of miscarriages in couples with recurrent pregnancy loss associated with a structural genetic factor have an unbalanced structural rearrangement (18, 19). Treatment options should be based on whether repeated miscarriages are euploid, aneuploid, or due to an unbalanced structural rearrangement and not exclusively on the parental carrier status. Currently, routine preimplantation embryo aneuploidy screening is not justified (20, 21).

If the evaluation of RPL identifies a remediable cause, cytogenetic analysis of subsequent losses can be employed to evaluate whether the event was random and not a treatment failure per se. Testing of the products of conception may also be of psychological value to the couple (6). There are pitfalls to this approach, however, including: the possibility of maternal tissue contamination of the specimen; failure to seek other causes of RPL if cytogenetic assessment reveals an abnormal karyotype; and the occurrence of non-cytogenetic embryonic abnormalities (e.g., dimorphic fetal development has been documented via hysteroscopy prior to dilatation and evacuation in the setting of normal fetal karyotype) (12). In the event that cytogenetic analysis of the products of conception reveals a 46,XX karyotype, reflex DNA extraction and analysis of a sample of maternal blood by means of microsatellite analysis can permit differentiation between a fetal source vs. maternal contamination (22).

Antiphospholipid Syndrome

The antiphospholipid syndrome is associated with recurrent pregnancy loss. The diagnostic criteria are outlined in Table 2 (23, 24). Although it is generally agreed that between 5% and 20% of patients with recurrent pregnancy loss will test positive for antiphospholipid antibodies (aPLs), the actual reported range varies between 8% and 42% (24, 25). Several groups of investigators have characterized these antibodies in laboratory-specific assays that have not been standardized (23). The most widely accepted tests are for lupus anticoagulant (LA), anticardiolipin antibody (aCL), and anti- B2 glycoprotein I (26) (see Table 3).

Antiphospholipid antibodies have a variety of effects on the trophoblast, including inhibition of villous cytotrophoblast differentiation and extravillous cytotrophoblast invasion into the decidua (27–31), induction of syncytiotrophoblast apoptosis (32), and initiation of maternal inflammatory pathways on the syncytiotrophoblast surface (33–36).

The identification of relevant antiphospholipid antibodies (aPLs) is one of the most contentious elements in the evaluation of autoimmune pregnancy loss. The aPLs are highly diverse and variable from patient to patient and are specific for a variety of cellular phospholipids and phospholipidbinding proteins. The aPLs may react directly with phospholipids, the protein co-factors bound to plastic (i.e., ELISA plates), or only when the co-factors are bound to phospholipids. Individual aPLs may be monospecific (reacting against only one antigen) or have varying degrees of cross-reactivity (reacting against multiple antigens).

With the exception of anticardiolipin, lupus anticoagulant, anti-ß2-glycoprotein I, and antiphosphatidylserine, clinical assays for antiphospholipid antibodies are not standardized and the level of evidence does not warrant routine screening. If screening for these additional aPLs is pursued, the statistical probability of finding a positive test will increase and will likely not reflect a true cause for RPL.

The most recent recommendations from the antiphospholipid consensus group list several clinical events that should trigger testing for aPLs (Table 2) (23). That group concluded that testing for aPLs is indicated in the setting of three or more unexplained spontaneous abortions before the 10th week of gestation when maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes have been excluded. A single unexplained loss of a morphologically normal fetus at or beyond 10 weeks of gestation also is considered to warrant testing for aPLs.

The standard treatment for documented antiphospholipid syndrome consists of low-dose aspirin and heparin (70 patients, 74.3% live-born rate) which was superior to treatment with aspirin alone (70 patients, 42.9% live-born rate) (37, 38). The combination of twice daily unfractionated heparin and low-dose aspirin appears to confer a significant benefit in pregnancies with aPLs and otherwise unexplained recurrent pregnancy loss; comparable efficacy of low molecular weight heparin has not been established (38, 39). Administration of prednisone does not improve pregnancy rates and may be associated with an increased risk of gestational hypertension and gestational diabetes (40).

In an analysis of 9 studies (n¼ 741) in which patients were initially selected because of preeclampsia, 17.9% of the patients with severe preeclampsia had moderate to high levels of aPLs (41–49). Thus, a history of a morphologically normal fetus delivered before 34 weeks because of severe preeclampsia/
eclampsia or placental insufficiency warrants testing for aPLs.

Table 2. International Consensus Classification criteria for the antiphospholipid syndrome (APS) (23, 24).

APS is present if one of the following clinical criteria and one of the laboratory criteria are met.
Clinical criteria
  1. Vascular thrombosis
  2. Pregnancy morbidity
    1. One or more unexplained deaths of morphologically normal fetuses after the 10th week of gestation by ultrasound or direct examination of the fetus.
    2. One or more premature births of a morphologically normal neonate before the 34th week of gestation because of eclampsia or severe pre-eclampsia or recognized features of placental insufficiency.
    3. Three or more unexplained consecutive spontaneous abortions before the 10th week of gestation with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded.
Laboratory criteria
  1. Lupus anticoagulant present in plasma on two or more occasions at least 12 weeks apart, or
  2. Anticardiolipin antibody of IgG or IgM isotype in serum or plasma present in medium or high titer (>40 GPL or MPL or > 99th percentile), on two or more occasions at least 12 weeks apart, or
  3. Anti-b2 glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma (in titer greater than the 99th percentile), present on two or more occasions at least 12 weeks apart.

Table 3. Antiphospholipid antibodies (aPLs).

Test Result Specificity
Lupus anticoagulant In vitro assays in which aPLs prevent
the initiation of clotting.
A mixture of aPLs that act in concert to bind phospholipids or phospholipid-binding proteins or both. Both activated partial thromboplastin time and dilute Russell’s viper venom time are suitable screening tests.
Serologic test for syphilis Recurrent false-positive test. Related to aPLs against cardiolipin, which is used in most screening tests for syphilis.
ELISAs for IgG, IgM, or IgA antibodies Highly specific and sensitive assays using purified antigens. Individual tests available for:

  • Cardiolipin (CL)
  • Phosphatidylserine (PS)
  • Phosphatidylethanolamine (PE)
  • Phosphatidylinositol (PI)
  • Phosphatidylglycerol (PG)
  • Phosphatidylcholine (PC)
  • Phosphatidic acid (PA)

Phospholipid-binding proteins:
  • b2-glycoprotein I (b2-GPI)
  • Activated protein C
  • Annexin A5
  • Clotting factors Xa, XII, and Va
  • Protein S Prothrombin
  • Thrombomodulin
  • Low and high molecular weight kininogens

Anatomic Factors

Congenital uterine abnormalities are associated with second trimester pregnancy loss in addition to other complications, including preterm labor, fetal malpresentation, and increased rates of cesarean delivery. Although the role of uterine malformations in first-trimester RPL is debatable, assessment of uterine anatomy is widely recommended (4–6, 9). Potentially relevant congenital M€ullerian tract anomalies include unicornuate, didelphic, bicornuate, septate, or arcuate uteri. These anomalies are often detected at the time of hysterosalpingography, and can be more fully characterized by either MRI or 3-D ultrasound imaging. A septate uterus is amenable to hysteroscopic surgical correction; there are no surgically corrective options for the unicornuate or didelphic uterus.

A review of a large number of studies concluded that congenital uterine anomalies were present in 4.3% (range from 2.7% to 16.7%) of the general population of fertile women and in 12.6% (range from 1.8% to 37.6%) of patients with recurrent pregnancy loss (2 or more consecutive losses) (50). A high incidence of pregnancy loss occurred in patients with septate (n ¼ 499, 44.3% loss), bicornuate (n ¼ 627, 36.0% loss), and arcuate (n ¼ 241, 25.7% loss) uteri. Correction of septate defects in particular may have beneficial effects (n ¼ 366, live birth rate 83.2%, range from 77.4% to 90.9%) and should be considered in women with RPL. The primary limitation of these data is the lack of randomized, controlled therapeutic trials.

The clinical management of pregnancy-loss patients with Asherman syndrome/intrauterine synechiae, uterine fibroids, and uterine polyps is also controversial, and there is no conclusive evidence that surgical treatment reduces the risk of pregnancy loss. Because randomized trials in this area are lacking and difficult to conduct, the general consensus is that surgical correction of significant uterine cavity defects should be considered. In the event of irreparable anatomic uterine abnormalities and RPL, IVF with transfer of embryos to an appropriately selected gestational carrier also may be a clinical consideration.

Inherited Thrombophilias

Screening for inherited thrombophilias (specifically, factor V Leiden and the prothrombin genemutations, protein C, protein S, and antithrombin deficiencies) may be clinically justified when a patient has a personal history of venous thromboembolism in the setting of a non-recurrent risk factor (such as surgery) or a first-degree relative with a known or suspected high-risk thrombophilia. Although an association between hereditary thrombophilias and fetal loss has been suggested (51, 52), prospective cohort studies have failed to confirm this (53, 54). Routine testing of women with RPL for inherited thrombophilias is not currently recommended (24, 55).

Hormonal and Metabolic Factors

It is generally agreed that maternal endocrine disorders (e.g., diabetes, thyroid dysfunction) should be evaluated and treated (56–59). As long as thyroid-stimulating hormone (TSH) levels are in the normal range, there is insufficient evidence to recommend routine thyroxine (T4) testing or screening for anti-thyroid antibodies (60). However, this is problematic given the lack of consensus regarding the definition of a normal upper limit of TSH. Whereas TSH values of 4.0–5.0 mIU/L were once considered normal, a consensus is emerging that TSH values above 2.5 mIU/L are outside the normal range. Well-controlled diabetes is not a risk factor for RPL. However, uncontrolled diabetes is associated with increased pregnancy loss (61).

Prolactin is commonly measured because elevated prolactin levels are associated with ovulatory dysfunction. Hyperprolactinemia may be associated with recurrent pregnancy loss through alterations in the hypothalamicpituitary-
ovarian axis, resulting in impaired folliculogenesis and oocyte maturation, and/or a short luteal phase. Normalization of prolactin levels with a dopamine agonist improved subsequent pregnancy outcomes in patients with recurrent pregnancy loss (62). Patients (n ¼ 64) with 2 or more pregnancy losses and hyperprolactinemia were treated with bromocriptine in their next pregnancy (62). Treatment resulted in an 85.7% live-born rate, whereas the untreated cohort had a 52.4% live-born outcome.

The role of other hormonal abnormalities remains controversial. Conceptually, delayed or late implantation may increase pregnancy losses (63). A shortened luteal phase has been associated with pregnancy loss but the assessment and interpretation of a putative luteal phase defect is problematic (64). The use of histologic and biochemical endpoints as diagnostic criteria for endometrial dating are unreliable and not reproducible utilizing the traditional histological criteria or other biochemical approaches (65). Therefore, routine endometrial biopsy for dating is not recommended, although continued research on the emerging molecular markers of endometrial development should be encouraged (66).

Administration of progesterone to women with sporadic miscarriages is ineffective (67, 68). However, in patients with three or more consecutive miscarriages immediately preceding their current pregnancy, empiric progestogen administration may be of some potential benefit (62, 69, 70).


Ureaplasma urealyticum, Mycoplasma hominus, chlamydia, Listeria monocytogenes, Toxoplasma gondii, rubella, cytomegalovirus, herpes virus, and other less frequent pathogens have been identified more frequently in vaginal and cervical cultures and serum from women with sporadic miscarriages (71). There are no convincing data that infections cause recurrent pregnancy loss. Therefore, there are no clear indications for routinely testing for these organisms in the RPL evaluation. Given the lack of prospective studies linking any infectious agent to recurrent early pregnancy loss, any use of antibiotics is not supported by the evidence.

Male Factors

Standard semen parameters, including sperm morphology, do not appear to be predictive of recurrent pregnancy loss (72).

Sperm aneuploidy and DNA fragmentation have been studied in couples with recurrent pregnancy loss (73). Abnormal DNA fragmentation may be seen in the setting of advanced paternal age or may result from correctable environmental factors, such as exogenous heat, toxic exposures, varicoceles, or increased reactive oxygen species in semen. Currently, there are contradictory data regarding a causal effect between pregnancy loss and fragmentation of sperm DNA in IVF cycles (74).

Although increased rates of sex chromosome disomy have been demonstrated in sperm from the male partner in couples with recurrent miscarriage, cytogenetic analysis of the products of conception from couples with RPL does not reveal an increased rate of sex chromosome aneuploidy, thus suggesting that such cytogenetically abnormal sperm may be selected against during fertilization (11, 75). Therefore, routine testing for spermploidy (e.g., fluorescence in situ hybridization [FISH]) or DNA fragmentation is not recommended.

Psychological Factors

It is clear that pregnancy loss exacts an immense psychological toll on affected couples and that an increased sensitivity to that effect is necessary throughout follow-up evaluations and during ensuing pregnancies (76, 77). The observed psychological response falls well within the normal bounds of a ‘‘grief response’’. Recurrent pregnancy loss patients are prone to heightened anger, depression, anxiety, and feelings of grief and guilt.

A possible psychological etiology for recurrent pregnancy loss was suggested by a published trial with expanded data in a later publication (78, 79). A cohort of 158 couples with R3 consecutive pregnancy losses and no otherwise identifiable etiology were divided into 2 groups, one receiving routine obstetrical care during the next pregnancy (n ¼ 42) and the other additionally receiving tender-loving care (TLC) (n ¼ 116). TLC was defined as psychological support with weekly medical and ultrasonographic examinations and instructions to avoid heavy work, travel, and sexual activity. The difference in live births was significant: 36% in the control group and 85% in the TLC group. These results should be interpreted with caution, however, as the groups were not randomized. Inclusion into the TLC or control group was based on residence; only those living ‘‘within a reasonable distance’’ of the hospital were offered TLC. The resultant differences in lifestyle, social support, and other psychological variables were unknown.

A psychological component in pregnancy loss was also suggested by a small prospective study of 45 pregnancies in patients with histories of 2 consecutive first-trimester miscarriages, with other causes eliminated (80). The patients completed a group of self-report questionnaires and interviews before their next pregnancy. Ten of the pregnancies (22.2%) resulted in a miscarriage, which was significantly predicted by the degree of baseline depressive symptoms.

Although the data to support a psychological role in the etiology of recurrent pregnancy loss are inconclusive, it is clearly advisable to offer these patients psychological support and counseling. Two non-randomized studies have shown significant improvement of subsequent pregnancy outcomes with close monitoring and support at a dedicated recurrent pregnancy loss clinic (81, 82).

Alloimmune Factors

Studies of human leukocyte antigen (HLA) typing, embryotoxic factors, decidual cytokine profiles, blocking or antipaternal antibody levels, HLA-G polymorphism, and other immunologic traits and factors have produced inconsistent data that generally have not been reproduced in more than one laboratory. Proposed immunomodulatory treatments for RPL in the setting of one or more of these findings have not been proven effective.

A meta-analysis of trials on paternal white blood cell immunization concluded that it had no beneficial effect (83). Treatment with intravenous immunoglobulin (IVIG) has also been proposed for unexplained pregnancy loss. However, several trials and meta-analyses concluded that IVIG is ineffective for primary recurrent pregnancy loss (84–88); thus, this treatment is not recommended.

Lifestyle, Environmental, Occupational Factors

Cigarette smoking has been suggested to have an adverse effect on trophoblastic function and is linked to an increased risk of sporadic pregnancy loss (89). Obesity has also been shown to be associated with an increased risk of RPL in women who conceive naturally (90). Other lifestyle habits such as cocaine use (91), alcohol consumption (3 to 5 drinks per week), and increased caffeine consumption (>3 cups of coffee, [92]) have been associated with risk of miscarriage.

Unexplained Recurrent Pregnancy Loss

No apparent causative factor is identified in 50% to 75% of couples with RPL. It is important to emphasize to patients with unexplained RPL that the chance for a future successful pregnancy can exceed 50%–60% depending on maternal age and parity (93, 94) (see Fig. 1).


  • The majority of miscarriages are sporadic and are thought to result from genetic causes that are greatly influenced by maternal age.
  • Recurrent pregnancy loss is defined by two or more failed clinical pregnancies.
  • Up to 50% of cases of RPL will not have a clearly defined etiology.


  • Evaluation of RPL can proceed after two consecutive clinical pregnancy losses.
  • Assessment of RPL focuses on screening for genetic factors and antiphospholipid syndrome, assessment of uterine anatomy, hormonal and metabolic factors, and lifestyle variables. These may include:
    • Peripheral karyotypic analysis of the parents
    • Screening for lupus anticoagulant, anticardiolipin antibodies, and anti-b2 glycoprotein I
    • Sonohysterogram, hysterosalpingogram, and/or hysteroscopy
    • Screening for thyroid or prolactin abnormalities
  • Karyotypic analysis of products of conception may be useful in the setting of ongoing therapy for RPL.
  • Women with persistent, moderate-to-high titers of circulating antiphospholipid antibodies can be treated with a combination of prophylactic doses of unfractionated heparin and low-dose aspirin.
  • Psychological counseling and support should be offered to couples with RPL.


This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Practice Committee and the Board of Directors of the American Society for Reproductive Medicine have approved this report.

The following members of the ASRM Practice Committee participated in the development of this document. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document.

Samantha Pfeifer, M.D.; Marc Fritz, M.D.; Jeffrey Goldberg, M.D.; R. Dale McClure, M.D.; Michael Thomas, M.D.; Eric Widra, M.D.; Glenn Schattman, M.D.; Mark Licht, M.D.; John Collins, M.D.; Marcelle Cedars, M.D.; Catherine Racowsky, Ph.D.; Owen Davis, M.D.; Kurt Barnhart, M.D., M.S.C.E.; Clarisa Gracia, M.D., MS.C.E.; William Catherino, M.D., Ph.D.; Robert Rebar, M.D.; Andrew La Barbera, Ph.D.


  1. Jacobs PA, Hassold T. Chromosome abnormalities: origin and etiology in abortions and livebirths. In: Vogel F, Sperling K, editors. Human genetics.
    Berlin: Springer-Verlag; 1987:233–44.
  2. van den Boogaard E, Kaandorp SP, Franssen MT, Mol BW, Leschot NJ, et al. Consecutive or non-consecutive recurrent miscarriage: is there any difference in carrier status? Hum Reprod 2010;25:1411–4.
  3. Stirrat GM. Recurrent miscarriage. Lancet 1990;336:673–5.
  4. Christiansen OB, Andersen A-MN, Bosch E, Daya S, Delves PJ, et al. Evidence-based investigations and treatments of recurrent pregnancy loss.
    Fert Steril 2005;83:821–39.
  5. Stephenson MD, Kutteh W. Evaluation and management of recurrent early pregnancy loss. Clin Obstet Gynecol 2007;50:132–45.
  6. Royal College of Obstetricians and Gynaecologists, Scientific Advisory Committee, Guideline No. 17. The Investigation and treatment of couples with
    recurrent miscarriage. Published May 2011. Available at: Accessed March 22, 2012.
  7. Stephenson MD. Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996;66:24–9.
  8. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil
    Steril 2010;93:1234–43.
  9. Rai R, Regan L. Recurrent miscarriage. Lancet 2006;368:601–11.
  10. Hassold T, Chiu D. Maternal age specific rates of numerical chromosome abnormalities with special reference to trisomy. Hum Genet 1985;70:11–7.
  11. Stephenson MD, Awartani KA, Robinson WP. Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study.
    Hum Reprod 2002;17:446–51.
  12. Philipp T, Philipp K, Reiner A, Beer F, Kalousek DK. Embroscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis
    of developmental defects of early failed pregnancies. Hum Reprod 2003;18: 1724–32.
  13. Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, et al. Incidence of early loss of pregnancy. N Eng J Med 1988;319:189–94.
  14. Edmonds DK, Lindsay KS, Miller JF, Williamson E, Wood PJ. Early embryonic mortality in women. Fertil Steril 1982;38:447–53.
  15. Knudsen UB, Hansen V, Juul S, Secher NJ. Prognosis of a new pregnancy following previous spontaneous abortions. Eur J Obstet Gynecol Reprod Biol
  16. Franssen MTM, Musters AM, van der Veen F, Repping S, Leschot NJ, et al. Reproductive outcome after PGD in couples with recurrent miscarriage carrying a structural chromosome abnormality: a systematic review. Hum Reprod Update 2011;17:467–75.
  17. Hirshfeld-Cytron J, Sugiura-Ogasawara M, Stephenson MD. Management of Recurrent Pregnancy loss associated with a parental carrier of a reciprocal
    translocation: a systematic review. Sem Reprod Med 2011;29:470–81.
  18. Sugiura-Ogasawara M, Ozaki Y, Sato T, Suzumori N, Suzumori K. Poor prognosis of recurrent aborters with either maternal or paternal reciprocal trans-
    locations. Fertil Steril 2004;81:367–73.
  19. Sierra S, Langlois S, Stephenson MD. Reproductive outcomes in patients with recurrent pregnancy loss associated with a structural chromosome ab-
    normality. Fertil Steril 2003;80:80–1.
  20. Sierra S, Stephenson M. Genetics of recurrent pregnancy loss. SemsReprod Med 2006;24:17–24.
  21. Vissenberg R, Goddijn M. Is there a role for assisted reproductive technology in recurrent miscarriage? Sem Reprod Med 2011;29:548–56.
  22. Jarrett KL, Michaelis RC, Phelan MC, Vincent VA, Best RG. Microsatellite analysis reveals a high incidence of maternal cell contamination in 46, XX
    products of conception consisting of villi or a combination of villi and membranous material. Am J Obstet Gynecol 2001;185:198–203.
  23. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, et al. International consensus statement on an update of the classification criteria for definite
    antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.
  24. ACOG. Antiphospholipid syndrome. ACOG Practice Bulletin, No.118, January 2011.
  25. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with
    other antiphospholipid antibodies. Fertil Steril 1996;66:540–6.
  26. Opartrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune
    disease: a metaanalysis. J Rheumatol 2006;33:2214–21.
  27. Adler RR, Ng AK, Rote NS. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol Reprod 1995;
  28. Rote NS, Lyden TW, Vogt E, Ng AK. Chapter 18: Antiphospholipid antibodies and placental development. In: Hunst JS, editor. Immunobiology of
    Reproduction. New York: Springer-Verlag; 1994:285–302.
  29. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic
    hormone production and invasion. Biol Reprod 1997;56:50–8.
  30. Di Simone N, Meroni PL, Del Papa N, Raschi E, Caliandro D, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered b2 -glycoprotein I. Arth Rheum 2000;43:140–50.
  31. Rote NS, Stetzer B. Autoimmune disease as a cause of reproductive failure. Clinics Lab Med 2003;23:265-93.
  32. Di Simone N, Castellani R, Caliandro D, Caruso A. Monoclonal anti-annexin V antibody inhibits trophoblast gonadotropin secretion and induces syncy-
    tiotrophoblast apoptosis. Biol Reprod 2001;65:1766–70.
  33. Vogt E, Ng AK, Rote NS. Antiphosphatidylserine antibody removes annexin V and facilitates the binding of prothrombin at the surface of a choriocarci-
    noma model of trophoblast differentiation. Amer J Obstet Gynecol 1997; 177:964–72.
  34. Rand JH. The pathogenic role of annexin-V in the antiphospholipid syndrome. Cure Rheumatol Rep 2000;2:246–51.
  35. Rand JH. The antiphospholipid syndrome. Ann Rev Med 2003;54:409–24.
  36. Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mole Immunol 2006;43:68–77.
  37. Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet
    Gynecol 2002;99:135–44.
  38. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. The Co-
    chrane Database of Systemic Reviews 2005;3.
  39. Ziakis PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss. A systematic review and meta-an-
    alyis. Obstet Gynecol 2010;115:1256–62.
  40. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JW, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent
    fetal loss. N Engl J Med 1997;337:148–53.
  41. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989;
  42. Sletnes KE, Wisloff F, Moe N, Dale PO. Antiphospholipid antibodies in preeclamptic women: relation to growth retardation and neonatal outcome.
    Acta Obstet Gynecol Scand 1992;71:112–7.
  43. Yamamoto T, Yoshimura S, Geshi Y, Sasamori Y, Okinaga S, Kobayashi T, Mori H. Measurement of antiphospholipid antibody by ELISA using purified
    beta 2-glycoprotein I in preeclampsia. Clin Exp Immunol 1993;94:196–200.
  44. Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, van Geijn HP. Underlying disorders associated with severe early-
    onset preeclampsia. Amer J Obstet Gynecol 1995;173:1042–8.
  45. Moodley J, Bhoota V, Duursma J, Pudifin D, Byrne S, Kennyer DG. The association of antiphospholipid antibodies with severe early onset pre-eclampsia.
    S Afr Med J 1995;85:105–7.
  46. Allen JY, Tapia-Santiago C, Kutteh WH. Antiphospholipid antibodies in patients with preeclampsia. Amer J Reprod Immunol 1996;36:81–5.
  47. Yamamoto T, Takahashi Y, Geshi Y, Sasamori Y, Mori H. Anti-phospholipid antibodies in preeclampsia and their binding ability for placental villous lipid
    fractions. J Obstet Gynaecol Res 1996;22:275–83.
  48. Van Pampus MG, Dekker GA, Wolf H, Huijgens PC, Koopman MM, von Blomberg BM, Buller HR. High prevalence of hemostatic abnormalities in
    women with a history of severe preeclampsia. Amer J Obstet Gynecol 1999;180:1146–50.
  49. Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies
    in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997;90:642–4.
  50. Grimbizis GF, Camus M, Tarlatzis BC, Bontis JN, Devroey P. Clinical implications of uterine malformations and hysteroscopic treatment results. Hum Re-
    prod Update 2001;7:161–74.
  51. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, Mercier E, RipartNeveu S, et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control ‘‘NOHA first’’ study. J Thromb Haemost 2005;3:2178–84.
  52. Preston FE, Rosendaal FR, Wlaher ID, Briet E, Berntorp E, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913–6.
  53. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother
    and fetus. Obstet Gynecol 2005;106:517–24.
  54. Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G Jr, et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010;115:
  55. De Jong PG, Goddijn M, Middwldorp S. Testing for inherited thrombophilia in recurrent miscarriage. Sem Reprod Med 2011;29:540–5.
  56. Mills JL, Simpson JL, Driscoll SG, Jovanovic-Peterson L, Van Allen M, et al. Incidence of spontaneous abortion among normal women and
    insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Eng J Med 1988;319:
  57. Hanson U, Persson B, Thunell S. Relationship between haemoglobin A1C in early type 1 (insulin-dependent) diabetic pregnancy and the occurrence of
    spontaneous abortion and fetal malformation in Sweden. Diabetologia 1990;33:100–4.
  58. Chang TI, Loeker MR. Genotoxicity and diabetic embryopathy: impaired expression of developmental control genes as cause of defective morphogen-
    esis. Semin Reprod Endocrinol 1999;17:153–65.
  59. Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002;12:
  60. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endo-
    crine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92: S1–47.
  61. Jovanovic L, Knopp H, Kim H, Cefalu WT, Zhu XD, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and
    diabetic pregnancies: evidence for a protective adaptation in diabetes. Diabetes Care 2005;28:1113–7.
  62. Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, Minaguchi H. Hyperprolactinemic recurrent miscarriage and results of randomized bromocrip-
    tine treatment trials. Fertil Steril 1998;70:246–52.
  63. Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. N Engl J Med 1999;340:1796–9.
  64. American Society for Reproductive Medicine. Clinical relevance of luteal phase deficiency. Fertil Steril 2012. In press. doi: 10.1016/j.fertnstert.2012.06.050.
  65. Murray MJ, Meyer WR, Zaino RJ, Lessey BA, Novotny DB, et al. A critical analysis of the accuracy, reproducibility, and clinical utility of histologic endome
    trial dating in fertile women. Fertil Steril 2004;81:1333–43.
  66. Coutifaris C, Myers ER, Guzick DS, Diamond MP, Carson SA, et al. Histological dating of timed endometrial biopsy tissue is not related to fertility status.
    Fertil Steril 2004;82:1264–72.
  67. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008;2.
  68. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet
    Gynaecol 1989;96:265–74.
  69. Oates-Whitehead RM, Haas DM, Carrier JA. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2003;4:CD003511.
  70. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Brit J Obstet Gynae-
    col 1989;96:275–80.
  71. Penta M, Lukic A, Conte MP, Chiarini F, Fioriti D, et al. Infectious agents in tissues from spontaneous abortions in the first trimester of pregnancy.
    New Microbiol 2003;26:329–37.
  72. Hill JA, Abbott AF, Politch JA. Sperm morphology and recurrent abortions. Fertil Steril 1994;61:776–8.
  73. Carrell DT, Liu L, Peterson CM, Jones KP, Hatasaka HH, Erickson L, Campbell B. Sperm DNA fragmentation is increased in couples with unex-
    plained recurrent pregnancy loss. Arch Androl 2003;49:49–55.
  74. Benchaib M, Lornage J, Mazoyer C, Lejeune H, Salle B, Francois Guerin J. Sperm deoxyribonucleic acid fragmentation as a prognostic in-
    dicator of assisted reproductive technology outcome. Fertil Steril 2007; 87:93–100.
  75. Rubio C, Gil-Salom M, Simon C, Vidal F, Rodrigo L, et al. Incidence of sperm chromosomal abnormalities in a risk population: relationship with sperm
    quality and ICSI outcome. Hum Reprod 2001;16:2084–92.
  76. Brier N. Understanding and managing the emotional reactions to a miscarriage. Obstet Gynecol 1999;93:151–5.
  77. Brier N. Anxiety after miscarriage: a review of the empirical literature and implications for clinical practice. Birth 2004;31:138–42.
  78. Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion.
    Amer J Obstet Gynecol 1984;148:140–6.
  79. Stray-Pedersen B, Stray-Pedersen S. Recurrent abortion: the role of psychotherapy. In: Beard RW, Ship F, editors. Early pregnancy loss: mechanisms and treatment. New York: Springer-Verlag; 1988:433–40.
  80. Sugiura-Ogasawara M, Furukawa TA, Nakano Y, Hori S, Aoki K, Kitamura T. Depression as a potential causal factor in subsequent miscarriage in recur-
    rent spontaneous aborters. Hum Reprod 2002;17:2580–4.
  81. Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997;12:387–9.
  82. Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod 1999;14:
  83. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. The Cochrane Database of Systemic Reviews 2006.
  84. Coulam CB, Krysa L, Stern JJ, Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34:333–7. 
  85. Christiansen OB, Mathiesen O, Husth M, Rasmussen KL, Ingerslev HJ, Lauritsen JG, Grunnet N. Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Hum Reprod 1995;10:2690–5.
  86. Stephenson MD, Dreher K, Houlihan E, Wu V. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: a prospective, randomized, double-blinded, placebo-controlled trial. Am J Reprod Immunol 1998;39:82–8.
  87. Hutton B, Sharma R, Fergusson D, Tinmouth A, Hebert P, Jamieson J, Walker M. Use of intravenous immunoglobulin for treatment of recur-
    rent miscarriage: a systematic review. Brit J ObstetGynecol 2007;114: 134–42.
  88. Ata B, Tan SL, Shehata F, Holzer H, Buckett W. A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscar-
    riage. Fertil Steril 2011;95:1080–5.
  89. Lindbohm ML, Sallmen M, Taskinen H. Effects of exposure to environmental tobacco smoke on reproductive health. Scand J Work Environ Health 2002;
    28(Suppl 2):84–6.
  90. Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous conception: a systematic review. Semin Reprod Med 2011;
  91. Ness RB, Grisso JA, Hirshinger N, Markovic N, Shaw LM, Day NL, et al. Cocaine and tobacco use and the risk of spontaneous abortion. N Engl J
    Med 1999;340:333–9.
  92. Kesmodel U, Wisborg K, Olsen SF, Henriksen TB, Secher NJ. Moderate alcohol intake in pregnancy and the risk of spontaneous abortion. Alcohol 2002;
  93. Andersen AN, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ 2000;320:
  94. Lund M, Kamper-Jørgensen M, Nielsen HS, Lidegaard Ø, Andersen AM, Christiansen OB. Prognosis for live birth in women with recurrent mis-
    carriage: what is the best measure of success? Obstet Gynecol 2012; 119:37–43.

Practice Documents

ASRM Practice Documents have been developed to assist physicians with clinical decisions regarding the care of their patients.
Practice Committee Documents teaser

Tobacco or marijuana use and infertility: a committee opinion (2023)

In the United States, approximately 21% of adults report some form of tobacco use, although 18% report marijuana use.
Practice Committee Documents teaser

Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline (2023)

Ovarian hyperstimulation syndrome is a serious complication associatedwith assisted reproductive technology.
Practice Committee Documents teaser

Definition of infertility: a committee opinion (2023)

‘‘Infertility’’ is a disease, condition, or status characterized by several factors.
Practice Committee Documents teaser

Clinical management of mosaic results from preimplantation genetic testing for aneuploidy of blastocysts: a committee opinion (2023)

This document incorporates studies about mosaic embryo transfer and provides evidence-based considerations for embryos with mosaic results on PGT-A.

More Resources

MAC 2021 teaser
ASRM Academy on the Go

ASRM MAC Tool 2021

The ASRM Müllerian Anomaly Classification 2021 (MAC2021) includes cervical and vaginal anomalies and standardize terminology within an interactive tool format.

View the MAC Tool
EMR Phrases teaser
Practice Guidance

EMR Shared Phrases/Template Library

This resource includes phrases shared by ASRM physician members to provide a template for individuals to create their own EMR phrases.

View the library
Practice Committee Documents teaser

ASRM Practice Documents

These guidelines have been developed by the ASRM Practice Committee to assist physicians with clinical decisions regarding the care of their patients.

View ASRM Practice Documents
Ethics Committee teaser

ASRM Ethics Opinions

Ethics Committee Reports are drafted by the members of the ASRM Ethics Committee on the tough ethical dilemmas of reproductive medicine.

View ASRM Ethics Opinions
Coding Corner general teaser
Practice Guidance

Coding Corner Q & A

The Coding Corner Q & A is a list of previously submitted and answered questions from ASRM members about coding. Answers are available to ASRM Members only.

View the Q & A
Covid-19 teaser
Practice Guidance

COVID-19 Resources

A compendium of ASRM resources concerning the Novel Corona virus (SARS-COV-2) and COVID-19.

View the resources
Couple looking at laptop for online patient education materials

Patient Resources provides a wide range of information related to reproductive health and infertility through patient education fact sheets, infographics, videos, and other resources.

View Website

Topic Resources

View more on the topic of miscarriage or recurrent pregnancy loss (RPL)
Videos Icon

Journal Club Global: Actualidad En Tratamientos De Fertilidad Para Pacientes Con Endometriosis

Live in Spanish from the 2024 Peruvian Fertility Society Meeting - Lima, Peru View the Video
Coding Icon

Recurrent Pregnancy Loss

Our reproductive endocrinologist sees patients for recurrent miscarriages. View the Answer
Coding Icon

Intralipids Infusion

Do you have any information on how to code for intralipid infusions? Our NP has indicated on the billing slip 36410, 96367, J7050. View the Answer
Coding Icon

Recurrent Pregnancy Loss (RPL)

Strategy for coding for a patient with RPL - codes compiled by the ASRM Coding Committee.  View the Coding Summary
Videos Icon

Journal Club Global: Prognosis in unexplained RPL

Recurrent pregnancy loss is one of the bigger challenges in the field of reproductive medicine. View the Video
Document Icon

Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline (2017)

This review evaluates if uterine myomas impact likelihood of pregnancy and pregnancy loss, and if myomectomy influences pregnancy outcomes. View the Guideline
Membership Icon

Early Pregnancy Special Interest Group (EPSIG)

Fostering increased interest in the biology, pathophysiology and clinical management of early pregnancy, sporadic  and recurrent pregnancy loss, implantation, early embryonic development and fetal demise. Learn more about the EPSIG